Skip to content

Feasibility trial of a respiratory symptom intervention

Feasibility randomised trial of a novel non-pharmacological intervention for the management of the respiratory distress symptom cluster (breathlessness, cough, fatigue) in patients with advanced lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN13173844
Enrollment
120
Registered
2012-10-11
Start date
2012-12-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Non-pharmacological, The core components of the non-pharmacological intervention would be teaching of: 1. Diaphragmatic breathing 2. Cough suppression techniques 3. Acupressure (chest points)

Sponsors

University of Manchester (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with primary or secondary lung cancer 2. Suffering from refractory breathlessness or cough or fatigue ie. not responding to current treatment for the past 2 weeks (presence of a minimum of two of the three symptoms) 3. In the presence of COPD, in stable condition 4. Karnofsky score>50% and Palliative Performance Scale [24] score of >60% 5. Expected prognosis of at least 3 months 6. 18+ years 7. Able to give informed consent 8. Patients are eligible even without the availability of a caregiver

Exclusion criteria

Exclusion criteria: 1. Unstable COPD or acute exacerbation of COPD 2. Rapidly worsening breathlessness requiring urgent medical intervention 3. Unstable cardiovascular, musculoskeletal or neuromuscular disease 4. Palliative radiotherapy to the chest < 4 weeks 5. Chemotherapy < 2 weeks

Design outcomes

Primary

MeasureTime frame
1. To explore the impact of a novel non-pharmacological supportive intervention on symptom distress 2. To identify the most valid and sensitive primary outcome measures Measured at baseline, 2 weeks and 12 weeks

Secondary

MeasureTime frame
No secondary outcome measures

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026